{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C5+Inhibitor", "query": { "intervention": "C5 Inhibitor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=C5+Inhibitor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T02:30:09.285Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03364153", "title": "Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stargardt's Macular Dystrophy" ], "interventions": [ { "name": "avacincaptad pegol", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 121, "start_date": "2018-01-12", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03364153" }, { "nct_id": "NCT04469465", "title": "Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Nocturnal Hemoglobinuria" ], "interventions": [ { "name": "Danicopan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "C5 Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2020-12-16", "completion_date": "2024-01-16", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 7, "location_summary": "Los Angeles, California • Weston, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469465" }, { "nct_id": "NCT07250750", "title": "A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myasthenia Gravis" ], "interventions": [ { "name": "IM-101 Part A", "type": "DRUG" }, { "name": "Placebo Part A", "type": "DRUG" }, { "name": "IM-101 Part B", "type": "DRUG" }, { "name": "Placebo Part B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunAbs Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 96, "start_date": "2026-02-05", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 8, "location_summary": "Altamonte Springs, Florida • Boca Raton, Florida • Naples, Florida + 4 more", "locations": [ { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250750" }, { "nct_id": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer (SCLC)", "Large Cell Neuroendocrine Cancer (LCNEC)", "Neuroendocrine Prostate Cancer (NEPC)", "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "Neuroendocrine Carcinomas (NEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)" ], "interventions": [ { "name": "Peluntamig (PT217)", "type": "DRUG" }, { "name": "Carboplatin + Etoposide", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Irinotecan (drug)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2023-09-05", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05652686" }, { "nct_id": "NCT05536297", "title": "Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Geographic Atrophy", "Age-Related Macular Degeneration" ], "interventions": [ { "name": "avacincaptad pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 278, "start_date": "2022-09-26", "completion_date": "2025-04-10", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 53, "location_summary": "Campbell, California • Fresno, California • Fullerton, California + 49 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05536297" }, { "nct_id": "NCT07221838", "title": "A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Generalized Myasthenia Gravis", "gMG" ], "interventions": [ { "name": "Oral Corticosteroid Tapering Schedule", "type": "PROCEDURE" }, { "name": "Ravulizumab", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2026-03-04", "completion_date": "2027-08-27", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 5, "location_summary": "Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Schaumburg", "state": "Illinois" }, { "city": "Neptune City", "state": "New Jersey" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221838" }, { "nct_id": "NCT06052839", "title": "Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-10-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052839" }, { "nct_id": "NCT04958265", "title": "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atypical Hemolytic Uremic Syndrome" ], "interventions": [ { "name": "Crovalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "28 Days to 17 Years" }, "enrollment_count": 41, "start_date": "2021-11-17", "completion_date": "2029-05-19", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 3, "location_summary": "Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04958265" }, { "nct_id": "NCT04435366", "title": "A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Geographic Atrophy", "Macular Degeneration" ], "interventions": [ { "name": "Avacincaptad Pegol", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IVERIC bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 448, "start_date": "2020-06-22", "completion_date": "2023-08-22", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 96, "location_summary": "Beverly Hills, California • Campbell, California • Fresno, California + 86 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435366" }, { "nct_id": "NCT04861259", "title": "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atypical Hemolytic Uremic Syndrome" ], "interventions": [ { "name": "Crovalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 83, "start_date": "2021-10-22", "completion_date": "2029-08-20", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-07T02:30:09.285Z", "location_count": 6, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04861259" } ] }